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TSH GWAS 
27,758 individuals with multiple 
measurements of TSH levels 
-TSH-GWAS done by imputing ~16 
million SNPs discovered in whole 
genome sequencing of 475 individuals  
22 SNPs associate with 
TSH levels at a 
significance threshold of 
P < 5E-08. 
Thyroid cancer association analysis 
The 21 SNPs, associated with levels of TSH, as well as all SNPs located within a 1.5 Mb region centered on 
each the SNP associating with TSH levels (the “proband” TSH-associated SNP) were checked for association 
with thyroid cancer by inspecting our thyroid cancer GWAS dataset. 
The thyroid cancer GWAS dataset is based on results from 222 directly genotyped patients and 657 patients 
with genotypes inferred using a genealogy-based imputation. The controls were matched and consisted of: 
24,198 directly genotyped individuals and 71,613 individuals with imputed genotypes. 
At one of 21 TSH- associated loci, the 2q35 loci, a different SNP from the “proband” TSH-SNP showed the 
strongest association with thyroid cancer. Therefore, this SNP, rs966423 was included in the confirmation 
genotyping of 22 SNPs in Icelandic thyroid cancer cases and controls. 
One SNP, rs965513 on 9q22.33, has 
been previously reported to associate 
with thyroid cancer and was therefore 
not studied further 
5 SNPs, located on 1p31.3, 1p36.13, 
2q35, 8p12 and 14q13.3, associate with 
thyroid cancer in Iceland at a significance 
threshold of P < 0.05. 
The five SNPs tested for association 
with thyroid cancer in external 
replication cases-control samples. 
The SNP on 1p31.3 had a 
suggestive combined P-value of 
6.6E-03 
The SNP 1p36.13 did not 
replicate 
3 SNPs, located on 2q35, 8p12 and 
14q13.3, associate with thyroid cancer at 
a significance threshold of P < 3E-09. 
Supplementary Figure 1. Summary of our study design and results      
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Supplementary Figure 2. Shown are the unadjusted (red diamonds) and adjusted (black circle) thyroid 
cancer association results (-log10 P-value) for rs944289 and rs116909374, as well as the recombination 
rate in 375 kb region on 14q13.3. The recombination rate (cM/Mb) is based on CEU HapMap phase II 
release 22. The association results are the combined unadjusted and adjusted results for the 4 study groups 
reported in Supplementary table 3.  
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Supplementary Figure 3. Shown is the OR for thyroid cancer (y-axis) and the TSH –effect (s.d.) (x-axis) 
for the 24 SNPs in Supplementary Table 2. The three red diamonds denote the three SNPs reported in 
Table 1 in the main text and are shown to associate with thyroid cancer at P < 3E-09. The two green 
diamonds denote the two previously reported thyroid cancer risk SNPs on 9q22.33 (rs965513) and 
14q13.3 (rs944289). The blue diamonds denote the remaining 17 SNPs listed in Supplementary Table 2. 
  
1.00
1.20
1.40
1.60
1.80
2.00
2.20
-0.20 -0.15 -0.10 -0.05 0.00 0.05 0.10 0.15 0.20
OR
TSH-effect (s.d.) 
Nature Genetics: doi:10.1038/ng.1046
5 
 
 
 
Supplementary Table 1b. The distribution of Icelandic thyroid cancer patients into different 
genotyping categories according to different phases of the thyroid cancer association study 
 
 
 
 
 
 
 
 
    a
 the Centaurus genotyped samples are a subset of the 657 imputed samples in the 
thyroid cancer GWAS. 
 
Supplementary Table 1a. An overview of the TSH, free-T4 and free-T3 measurements 
available for SNP-chip genotyped individuals. 
Measurement 
type 
(units) 
Males 
with 
measure-
ments 
(n) 
Measure-
ments per 
male 
individuala 
(n) 
Females 
with 
measure-
ments 
(n) 
Measure-
ments per 
female 
individuala 
(n) 
The median of 
measurements 
(first quartile, 
last quartile) 
TSH 
(mIU/L) 10,434 4.4 17,324 6.1 
1.94 
(1.14, 3.16) 
Free-T4 
(pmol/L) 6,188 3.0 12,872 4.1 
15.7 
(13.8, 18.2) 
Free-T3 
(pmol/L) 2,981 2.3 7,044 2.8 
4.6 
(4.0, 5.3) 
aThe geometric mean of the number of measurements per individual 
i) Thyroid cancer GWAS 
Sample categories Patients (n) 
Chip genotypes 222 
Imputed genotypes 657 
Neither with chip nor imputed genotypes 139 
Total number of thyroid cancer patients 1,018 
  ii) Confirmation of thyroid cancer association by direct genotyping 
Sample categories Patients (n) 
Chip genotyped 222 
Centaurus genotyped a 339 
Neither with chip nor Cenataurus genotypes 457 
Total number of thyroid cancer patients 1,018 
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Supplementary Table 2. Association results in Iceland for serum levels of TSH,  free-T3, free-T4, thyroid cancer, and goiter risk 
TSH levels 
(n = 27,758) 
Thyroid cancer 
GWAS 
results 
(n = 222+657)a 
Association results for directly genotyped thyroid cancer cases 
and controls 
free T4 levels 
(n = 19,060) 
free T3 levels 
(n = 10,023) 
Goiter 
GWAS results 
(n = 217 +329) a 
SNP_Effect 
Allele Chr. 
Position 
B36 (bp) 
Effect 
(s.d.) P-value OR P-value OR P-value 
Cases 
(n) 
Cases 
(freq.) 
Controls 
(n) 
Controls 
(freq.) 
Effect 
(s.d.) P-value 
Effect 
(s.d.) P-value OR P-value 
rs10799824_A 1 19,713,761 -0.099 3.8E-26 1.25 1.4E-02 1.26 0.012 524 0.183 2,330 0.151 0.030 3.7E-03 0.016 2.9E-01 1.36 2.4E-03 
rs334725_C 1 61,382,637 -0.130 1.0E-20 1.27 6.8E-02 1.34 0.014 561 0.086 40,013 0.065 0.038 1.5E-02 0.023 3.0E-01 1.60 8.6E-04 
rs17020124_G 1 108,159,534 -0.091 4.3E-17 1.16 1.9E-01 1.05 0.7 542 0.887 1,499 0.882 0.020 9.8E-02 0.026 1.3E-01 0.89 3.6E-01 
rs11694732_C 2 1,387,357 0.045 1.6E-10 0.96 5.2E-01 1.06 0.43 545 0.415 3,179 0.401 -0.018 2.0E-02 0.012 2.9E-01 1.00 9.8E-01 
rs737308_T 2 217,331,494 -0.072 5.7E-22 1.08 3.1E-01 1.09 0.26 547 0.333 3,151 0.314 0.029 3.8E-04 0.009 4.5E-01 1.08 3.4E-01 
rs966423_C 2 218,018,585 -0.032 2.9E-06 1.25 1.0E-03 1.26 3.8E-04 546 0.499 38,854 0.442 0.020 9.7E-03 0.006 5.7E-01 1.08 3.5E-01 
rs10030849_C 4 149,872,549 0.066 1.1E-14 1.06 5.0E-01 1.07 0.48 539 0.798 1,500 0.787 -0.001 8.8E-01 -0.012 3.6E-01 1.05 6.0E-01 
rs2046045_A 5 76,571,567 -0.119 2.8E-62 0.92 2.7E-01 1.02 0.76 561 0.622 39,165 0.617 0.009 2.5E-01 0.008 4.6E-01 1.10 2.3E-01 
rs729761_T 6 43,912,549 -0.085 7.5E-28 0.89 1.4E-01 1.00 0.99 543 0.263 38,820 0.263 0.021 1.7E-02 0.022 8.6E-02 1.20 4.0E-02 
rs6923866_T 6 44,009,162 0.048 5.4E-09 1.01 9.3E-01 1.13 0.16 545 0.809 3,118 0.789 -0.019 4.1E-02 0.014 2.8E-01 0.76 2.4E-03 
rs3008043_A 6 165,972,622 -0.076 2.0E-23 1.15 6.5E-02 1.09 0.29 536 0.314 1,476 0.296 0.012 1.7E-01 0.003 7.8E-01 1.03 7.3E-01 
rs2439302_G 8 32,551,911 -0.048 7.8E-12 1.34 2.4E-05 1.41 1.3E-06 532 0.535 3,094 0.449 0.008 3.3E-01 -0.002 8.6E-01 0.99 8.9E-01 
rs965513_A 9 99,595,930 -0.083 4.3E-31 1.71 6.9E-15 1.70 3.0E-18 558 0.480 43,108 0.352 -0.040 7.84E-07 0.024 4.0E-02 0.77 2.4E-03 
rs7913135_C 10 101,308,629 0.046 2.8E-11 0.91 1.8E-01 1.00 0.98 502 0.484 1,494 0.484 -0.025 1.1E-03 0.006 5.8E-01 0.95 5.6E-01 
rs7128207_G 11 45,186,637 -0.042 1.3E-09 1.05 5.2E-01 1.07 0.35 545 0.472 2,135 0.455 0.023 3.0E-03 0.011 3.2E-01 1.05 5.7E-01 
rs61938844_A 12 95,107,989 0.190 5.6E-16 1.17 4.7E-01 1.10 0.69 544 0.028 1,610 0.025 -0.020 4.3E-01 -0.081 3.5E-02 0.98 9.4E-01 
rs944289_T 14 35,718,997 -0.022 1.5E-03 1.42 5.6E-07 1.36 5.2E-07 560 0.632 39,864 0.558 0.017 2.7E-02 -0.003 7.8E-01 1.05 5.4E-01 
rs116909374_T 14 35,808,112 -0.141 1.1E-16 1.61 1.5E-03 2.03 5.4E-07 542 0.085 3,190 0.044 0.041 2.8E-02 0.039 1.4E-01 1.24 2.2E-01 
rs34269820_T 14 92,635,908 -0.083 7.9E-19 1.11 2.7E-01 1.02 0.85 545 0.835 1,496 0.832 0.016 1.1E-01 0.015 3.1E-01 1.25 4.4E-02 
rs73362602_T 14 104,301,640 0.039 4.1E-08 0.91 2.1E-01 1.01 0.85 536 0.466 1,496 0.463 -0.003 7.5E-01 -0.021 7.0E-02 0.92 3.1E-01 
rs73398284_T 15 47,501,692 0.059 4.9E-14 0.95 4.7E-01 1.02 0.81 526 0.726 1,472 0.722 -0.021 1.4E-02 -0.022 6.9E-02 0.66 1.0E-06 
rs7190187_T 16 78,292,679 -0.077 3.8E-24 1.19 1.7E-02 1.03 0.75 541 0.310 1,475 0.304 0.013 1.2E-01 0.021 9.0E-02 1.09 3.1E-01 
rs10420008_G 19 7,185,575 0.045 4.3E-08 0.87 9.2E-02 1.03 0.76 535 0.223 1,499 0.218 -0.009 3.4E-01 -0.026 5.6E-02 0.78 9.8E-03 
rs6082762_Ab 20 22,573,016 -0.082 3.5E-19 1.04 6.7E-01 1.01 0.85 531 0.193 39,034 0.191 0.021 4.0E-02 0.006 6.7E-01 1.35 2.0E-03 
Association results are for the effect-allele of the 24 SNPs. 21 were selected based on a P-values threshold (P < 5E-08) for an association with serum levels of TSH, one SNP (rs966423) was selected based on its stronger two-
way association with thyroid cancer, also included are the two previously published thyroid cancer risk SNPs; rs965513 on 9q22.33 and rs944289 on 14q13.3. The effect size for serum levels of TSH, free-T3 and free-T4 is 
measured in standard-deviation units (s.d.). The minus (-) sign in front of the effect size stands for a decreasing effect whereas no sign stands for an increasing effect.  a The thyroid cancer GWAS results are based on 222 chip 
genotyped cases and 657 cases genotyped using imputation (two-way imputation) and chip genotyped 1st or 2nd degree relatives; for goiter the corresponding numbers are 217 chip genotyped patients and 329 patents with chip 
genotyped 1st or 2nd degree relatives. b The SNP rs6082762 is not on the chips used genotype the Icelandic samples and the single track assay failed in production therefore are the association results for the directly genotyped 
cases and controls based on data from a fully correlated SNP rs1203930  (r2 = and D’ = 1 between rs6082762 and rs1203930 according to CEU HapMap data) genotyped using the Illumina chips. 
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Supplementary Table 3. Association results for rs334725 located on 1p31.3 and thyroid 
cancer in Iceland, the Netherlands, Spain and the United States 
Study population 
(n cases/n controls) OR 95% CI P-value 
Case 
(freq) 
Controls 
(freq) 
rs334725_C on 1p31.3 
    Iceland (561/40,013) a 1.34 (1.06, 1.70) 0.014 0.086 0.065 
The Netherlands (149/832) 1.22 (0.73, 2.05) 0.45 0.054 0.044 
Ohio, US (357/373) 1.28 (0.77, 2.13) 0.34 0.056 0.044 
Spain (89/1,399) 0.93 (0.00, ∞) 1.00 0.039 0.042 
All combined (1,156/42,617)b 1.31 (1.08, 1.60) 6.6×10-3 - - 
ars334725 is present on the Illumina chips used to genotype the Icelandic GWAS population, 
results are included for chip-genotyped individuals. Otherwise all results for all study groups 
are based on single-track assay genotyping. 
bFor the combined study populations, the OR and the P value were estimated using the Mantel-
Haenszel model 
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Supplementary Table 4. Association results for rs116909374 and 
rs944289 on 14q13.3, before and after adjustment 
Study group rs116909374_T 
 
rs944289_T 
Iceland OR P-value 
 
OR P-value 
Unadjusted 2.03 5.4E-07 
 
1.36 4.2E-05 
Adjusted 1.95 4.7E-07 
 
1.30 9.6E-05 
The Netherlands      
Unadjusted 1.95 0.024 
 
1.39 0.013 
Adjusted 1.93 0.028 
 
1.38 0.014 
Ohio a      
Unadjusted 1.60 0.26  1.51 0.0067 
Adjusted 1.52 0.32   1.50 0.0078 
Spain      
Unadjusted 3.37 0.0026 
 
1.17 0.31 
Adjusted 3.27 0.0040   1.13 0.45 
All combined      
Unadjusted 2.07 5.0×10-10  1.36 4.9×10-8 
Adjusted 1.99 8.7×10-10  1.32 1.9×10-7 
Shown are results for rs116909374 before and after being adjusted 
for rs944289 as well as results for rs944289 before and after being 
adjusted for rs116909374. The two SNPs are only correlated to a 
very small degree (D' = 0.35 and r2 = 0.005 based on results from 
3,693 Icelanders). Results are only presented for individuals where 
data is available for both SNPs. Phet is > 0.5 for both markers. 
aFor the Ohio samples data was available for both SNPs for 155 
cases and 245 controls. 
The LD- and correlation information the two SNPs in this table in 
the four different study groups is as follows: 
Iceland; D’ = 0.35 r2 = 0.0050 
The Netherlands D’ = 0.13  r2 = 0.0003 
Spain; D’ = 0.63 r2 = 0.0065 
Ohio; D’ = 0.37 r2 = 0.0026 
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Supplementary Note 
 
Genotyping Methods 
Illumina genotyping. The Icelandic chip-typed samples were assayed with the Illumina Human 
Hap300, Hap CNV370, Hap 610, 1M or Omni-1 Quad bead chips at deCODE genetics. Only the 
317,503 SNPs from the Human Hap300 chip were used in the long range phasing and the 
subsequent SNP imputations. SNPs were excluded if they had (i) yield lower than 95%, (ii) minor 
allele frequency less than 1% in the population or (iii) significant deviation from Hardy-
Weinberg equilibrium in the controls (P < 0.001), (iv) if they produced an excessive inheritance 
error rate (over 0.001), (v) if there was substantial difference in allele frequency between chip 
types (from just a single chip if that resolved all differences, but from all chips otherwise). All 
samples with a call rate below 97% were excluded from the analysis. The final set of SNPs used 
for long range phasing and GWAS was composed of 297,835 autosomal SNPs.  
Single track assay SNP genotyping. Genotyping of the SNPs reported in Table 1 of the main text 
for the three case-control groups from Iceland, the Netherlands and Spain was carried out by 
deCODE Genetics in Reykjavik, Iceland, applying the Centaurus1 (Nanogen) platform or the 
Illumin SNP-chips. Using the Centaurus single-track assay, we genotyped the Spanish cases and 
controls, the Dutch cases and controls and all the 561 Icelandic patients. Of the Icelandic patients, 
222 had been previously chip genotyped for the SNPs on 1p31.3 and 2q35which are present on 
the Illuimina SNP-chips used in our initial GWAS genotyping effort. These 222 patients were re-
genotyped using Centaurus single-track assay for confirming data consistency of the two 
genotyping platforms. We used Centaurus single-track assay to genotype between 1,472 and 
3,190 Icelandic controls for the 21 TSH-associated SNPs. For the four TSH-associated SNPs that 
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are present on the Illumina chips we included genotype data from 40,013 Icelandic controls 
GWAS study population. The 3,190 single-track assay genotyped controls are among the 40,013 
Illumin chip genotyped controls and the overlap of genotype results was used to check for data 
consistency. Furthermore, the quality of each Centaurus SNP assay was evaluated by genotyping 
it in the CEU and/or YRI HapMap samples and comparing the results with the HapMap publicly 
released data. Assays with >1.5% mismatch rate were not used and a linkage disequilibrium (LD) 
test was used for markers known to be in LD. 
Genotyping of samples from the Ohio study populations was done using the SNaPshot (PE 
Applied Biosystems,Foster City, CA) genotyping platform at the Ohio State University, as 
previously described2. 
Whole Genome Sequencing. SNPs were imputed based on unpublished data from the Icelandic 
whole genomic sequencing project (457 Icelandic individuals) selected for various neoplasic, 
cardiovascular and psychiatric conditions. All of the individuals were sequenced to a depth of at 
least 10X. Sixteen million SNPs were imputed based on this set of individuals. 
Sample preparation. Paired-end libraries for sequencing were prepared according to the 
manufacturer's instructions (Illumina). In short, approximately 5 µg of genomic DNA, isolated 
from frozen blood samples, was fragmented to a mean target size of 300 bp using a Covaris E210 
instrument. The resulting fragmented DNA was end repaired using T4 and Klenow polymerases 
and T4 polynucleotide kinase with 10 mM dNTP followed by addition of an 'A' base at the ends 
using Klenow exo fragment (3′ to 5′-exo minus) and dATP (1 mM). Sequencing adaptors 
containing 'T' overhangs were ligated to the DNA products followed by agarose (2%) gel 
electrophoresis. Fragments of about 400 bp were isolated from the gels (QIAGEN Gel Extraction 
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Kit), and the adaptor-modified DNA fragments were PCR enriched for ten cycles using Phusion 
DNA polymerase (Finnzymes Oy) and PCR primers PE 1.0 and PE 2.0 (Illumina). Enriched 
libraries were further purified using agarose (2%) gel electrophoresis as described above. The 
quality and concentration of the libraries were assessed with the Agilent 2100 Bioanalyzer using 
the DNA 1000 LabChip (Agilent). Barcoded libraries were stored at −20 °C. All steps in the 
workflow were monitored using an in-house laboratory information management system with 
barcode tracking of all samples and reagents. 
DNA sequencing. Template DNA fragments were hybridized to the surface of flow cells 
(Illumina PE flowcell, v4) and amplified to form clusters using the Illumina cBot. In brief, DNA 
(8–10 pM) was denatured, followed by hybridization to grafted adaptors on the flowcell. 
Isothermal bridge amplification using Phusion polymerase was then followed by linearization of 
the bridged DNA, denaturation, blocking of 3 ends and hybridization of the sequencing primer. 
Sequencing-by-synthesis was performed on Illumina GAIIx instruments equipped with paired-
end modules. Paired-end libraries were sequenced using 2 × 101 cycles of incorporation and 
imaging with Illumina sequencing kits, v4. Each library or sample was initially run on a single 
lane for validation followed by further sequencing of ≥4 lanes with targeted cluster densities of 
250–300 k/mm2. Imaging and analysis of the data was performed using the SCS 2.6 and RTA 1.6 
software packages from Illumina, respectively. Real-time analysis involved conversion of image 
data to base-calling in real-time. 
Alignment. For each lane in the DNA sequencing output, the resulting qseq files were converted 
into fastq files using an in-house script. All output from sequencing was converted, and the 
Illumina quality filtering flag was retained in the output. The fastq files were then aligned against 
Build 36 of the human reference sequence using bwa version 0.5.7 (ref. 3). 
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BAM file generation. SAM file output from the alignment was converted into BAM format using 
SAMtools version 0.1.8 (ref. 4), and an in-house script was used to carry the Illumina quality 
filter flag over to the BAM file. The BAM files for each sample were then merged into a single 
BAM file using SAMtools. Finally, Picard version 1.17 (see http://picard.sourceforge.net/) was 
used to mark duplicates in the resulting sample BAM files. 
SNP calling and genotyping in whole-genome sequencing. A two-step approach was applied. The 
first step was to detect SNPs by identifying sequence positions where at least one individual 
could be determined to be different from the reference sequence with confidence (quality 
threshold of 20) based on the SNP calling feature of the pileup tool SAMtools4. SNPs that always 
differed heterozygous or homozygous from the reference were removed. The second step was to 
use the pileup tool to genotype the SNPs at the positions that were flagged as polymorphic. 
Because sequencing depth varies and hence the certainty of genotype calls also varies, genotype 
likelihoods rather than deterministic calls were calculated (see below). Of the 2.5 million SNPs 
reported in the HapMap2 CEU samples, 96.3% were observed in the Icelandic whole-genome 
sequencing data. Of the 6.9 million SNPs reported in the 1000 Genomes Project data, 89.4% were 
observed in the Icelandic whole-genome sequencing data. 
Statistical analysis 
Long range phasing. Long range phasing of all chip-genotyped individuals was performed with 
methods described previously5-9. In brief, phasing is achieved using an iterative algorithm which 
phases a single proband at a time given the available phasing information about everyone else 
that shares a long haplotype identically by state with the proband. Given the large fraction of the 
Nature Genetics: doi:10.1038/ng.1046
13 
 
Icelandic population that has been chip-typed, accurate long range phasing is available genome-
wide for all chip-typed Icelanders. 
Genotype imputation. We imputed the SNPs identified and genotyped through sequencing into all 
Icelanders who had been phased with long range phasing using the same model as used by 
IMPUTE10. The genotype data from sequencing can be ambiguous due to low sequencing 
coverage. In order to phase the sequencing genotypes, an iterative algorithm was applied for each 
SNP with alleles 0 and 1. We let H be the long range phased haplotypes of the sequenced 
individuals and applied the following algorithm: 
1. For each haplotype h in H, use the Hidden Markov Model of IMPUTE to calculate for 
every other k in H, the likelihood, denoted γh,k, of h having the same ancestral source as k 
at the SNP. For every h in H, initialize the parameter θh, which specifies how likely the 
one allele of the SNP is to occur on the background of h from the genotype likelihoods 
obtained from sequencing. The genotype likelihood Lg is the probability of the observed 
sequencing data at the SNP for a given individual assuming g is the true genotype at the 
SNP. If L0, L1 and L2 are the likelihoods of the genotypes 0, 1 and 2 in the individual that 
carries h, then set  =



	
. 
 
2. For every pair of haplotypes h and k in H that are carried by the same individual, use the 
other haplotypes in H to predict the genotype of the SNP on the backgrounds of h and k: 

 = ∑ ,∈∖{}  and 
 = ∑ ,∈∖{} . Combining these predictions with the 
genotype likelihoods from sequencing gives un-normalized updated phased genotype 
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probabilities:  = 1 − 
1 − 
,  = 
1 − 
,  = 1 − 




 and 
 = 

.  
3. Now use these values to update θh and θk to  =
	
				
 and  =
	
				
. 
4. Repeat step 3 when the maximum difference between iterations is greater than a 
convergence threshold ε. We used ε=10−7. 
Given the long range phased haplotypes and θ, the allele of the SNP on a new haplotype h not in 
H, is imputed as ∑ ,∈ . 
The above algorithm can easily be extended to handle simple family structures such as parent-
offspring pairs and triads by letting the P distribution run over all founder haplotypes in the 
family structure. The algorithm also extends trivially to the X-chromosome. If source genotype 
data are only ambiguous in phase, such as chip genotype data, then the algorithm is still applied, 
but all but one of the Ls will be 0. In some instances, the reference set was intentionally enriched 
for carriers of the minor allele of a rare SNP in order to improve imputation accuracy. In this 
case, expected allele counts will be biased toward the minor allele of the SNP. Call the 
enrichment of the minor allele E and let θ′ be the expected minor allele count calculated from the 
naïve imputation method, and let θ be the unbiased expected allele count, then  =  !
"! !
	and 
hence  = !
 " !
. 
This adjustment was applied to all imputations based on enriched imputations sets. We note that 
if θ′ is 0 or 1, then θ will also be 0 or 1, respectively. 
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In-silico genotyping. In addition to imputing sequence variants from the whole genome 
sequencing effort into chip genotyped individuals, we also performed a second imputation step 
where genotypes were imputed into relatives of chip genotyped individuals, creating in-silico 
genotypes. The inputs into the second imputation step are the fully phased (in particular every 
allele has been assigned a parent of origin) imputed and chip type genotypes of the available chip 
typed individuals. The algorithm used to perform the second imputation step consists of: 
1. For each ungenotyped individual (the proband), find all chip genotyped individuals within 
two meiosis of the individual. The six possible types of two meiosis relatives of the 
proband are (ignoring more complicated relationships due to pedigree loops): Parents, full 
and half siblings, grandparents, children and grandchildren. If all pedigree paths from the 
proband to a genotyped relative go through other genotyped relatives, then that relative is 
excluded. E.g. if a parent of the proband is genotyped, then the proband’s grandparents 
through that parent are excluded. If the number of meiosis in the pedigree around the 
proband exceeds a threshold (we used 12), then relatives are removed from the pedigree 
until the number of meiosis falls below 12, in order to reduce computational complexity. 
2. At every point in the genome, calculate the probability for each genotyped relative 
sharing with the proband based on the autosomal SNPs used for phasing. A multipoint 
algorithm based on the hidden Markov model Lander-Green multipoint linkage algorithm 
using fast Fourier transforms is used to calculate these sharing probabilities34,35. First 
single point sharing probabilities are calculated by dividing the genome into 0.5cM bins 
and using the haplotypes over these bins as alleles. Haplotypes that are the same, except at 
most at a single SNP, are treated as identical. When the haplotypes in the pedigree are 
incompatible over a bin, then a uniform probability distribution was used for that bin. The 
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most common causes for such incompatibilities are recombinations in member belonging 
to the pedigree, phasing errors and genotyping errors. Note that since the input genotypes 
are fully phased, the single point information is substantially more informative than for 
unphased genotyped, in particular one haplotype of the parent of a genotyped child is 
always known. The single point distributions are then convolved using the multipoint 
algorithm to obtain multipoint sharing probabilities at the center of each bin. Genetic 
distances were obtained from the most recent version of the deCODE genetic map6. 
3. Based on the sharing probabilities at the center of each bin, all the SNPs from the whole 
genome sequencing are imputed into the proband. To impute the genotype of the paternal 
allele of a SNP located at $, flanked by bins with centers at $%&' and $()*'. Starting with 
the left bin, going through all possible sharing patterns +, let ,- be the set of haplotypes of 
genotyped individuals that share identically by descent within the pedigree with the 
proband’s paternal haplotype given the sharing pattern + and + be the probability of + 
at the left bin – this is the output from step 2 above – and let .) be the expected allele 
count of the SNP for haplotype /. Then .- =
∑ %00∈12
∑ 0∈12
 is the expected allele count of the 
paternal haplotype of the proband given + and an overall estimate of the allele count 
given the sharing distribution at the left bin is obtained from .%&' = ∑ +.-- . If ,- is 
empty then no relative shares with the proband’s paternal haplotype given + and thus 
there is no information about the allele count. We therefore store the probability that some 
genotyped relative shared the proband’s paternal haplotype, 3%&' = ∑ 4-,526∅  and an 
expected allele count, conditional on the proband’s paternal haplotype being shared by at 
least one genotyped relative: 8%&' =
∑ -%22,129∅
∑ -2,129∅
. In the same way calculate 3()*' and 
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8()*'. Linear interpolation is then used to get an estimates at the SNP from the two 
flanking bins:  
3 = 3%&' +
$ − $%&'
$()*' − $%&'
;3()*' − 3%&'<, 
8 = 8%&' + $ − $%&'$()*' − $%&' ;8()*' − 8%&'<. 
 
If  is an estimate of the population frequency of the SNP then 38 + (1 − 3) is an estimate of 
the allele count for the proband’s paternal haplotype. Similarly, an expected allele count can be 
obtained for the proband’s maternal haplotype. 
Genotype imputation information. The informativeness of genotype imputation was estimated by 
the ratio of the variance of imputed expected allele counts and the variance of the actual allele 
counts: 
4>?(@(|8ℎ/C D>E>))4>?() , 
where  ∈ {0, 1} is the allele count. 4>?(@(|8ℎ/C D>E>)) was estimated by the observed 
variance of the imputed expected counts and 4>?() was estimated by C(1 − C), where C is the 
allele frequency. For the present study, when imputed genotypes are used, the information value 
for all SNPs is between 0.92 and 0.99. 
Case control association testing. Logistic regression was used to test for association between 
SNPs and disease, treating disease status as the response and expected genotype counts from 
imputation or allele counts from direct genotyping as covariates. Testing was performed using the 
likelihood ratio statistic. When testing for association based on the in silico genotypes, controls 
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were matched to cases based on the informativeness of the imputed genotypes, such that for each 
case G controls of matching informativeness where chosen. Failing to match cases and controls 
will lead to a highly inflated genomic control factor, and in some cases may lead to spurious false 
positive findings. The informativeness of each of the imputation of each one of an individual’s 
haplotypes was estimated by taking the average of 
>(., ) = H. − 1 −  ,     . ≥  − . ,     . <  
over all SNPs imputed for the individual, where . is the expected allele count for the haplotype at 
the SNP and  is the population frequency of the SNP. Note that >(, ) = 0 and >(0, ) =
>(1, ) = 1. The mean informativeness values cluster into groups corresponding to the most 
common pedigree configurations used in the imputation, such as imputing from parent into child 
or from child into parent. Based on this clustering of imputation informativeness we divided the 
haplotypes of individuals into seven groups of varying informativeness, which created 27 groups 
of individuals of similar imputation informativeness; 7 groups of individuals with both 
haplotypes having similar informativeness, 21 groups of individuals with the two haplotypes 
having different informativeness, minus the one group of individuals with neither haplotype 
being imputed well. Within each group we calculate the ratio of the number of controls and the 
number of cases, and choose the largest integer G that was less than this ratio in all the groups. 
For example, if in one group there are 10.3 times as many controls as cases and if in all other 
groups this ratio was greater, then we would set G = 10 and within each group randomly select 
ten times as many controls as there are cases. For thyroid cancer we used G = 109 and for goiter 
we used G = 186. 
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For the 24 SNPs reported in Suppl. Table 2 we compared the correlation between the imputed 
and directly generated genotype. Based on a minimum of 1,545 individuals with both imputed 
and single track generated genotypes we calculated the correlation coefficient (r). The range of 
the correlation is between 0.92 and 1.00. The second lowest correlation value was 0.96 and the 
median value was 0.98. 
Quantitative trait association testing. The normalized and adjusted measurements of TSH, FT3 
and FT4were regressed on allele counts using classical linear regression. 
Sibling recurrence risk ratio: 
The sibling recurrence risk ratio is defined as )()(
)(
)(
)|(
BPAP
ABP
AP
BAP
sibling ==λ , where A is the 
event that a person gets a disease and B is the event that a particular sibling of the person gets the 
disease. Assuming a multiplicative model, the λsibling accounted for by a variant with frequency f 
and relative risk of r is equal to 
[ ]
4
222
4
1
)1(
)1(1
ffr
ffrffr
−+
−++−+
 
 
Inflation factor adjustment. In order to account for the relatedness and stratification within our 
case and control sample sets we applied the method of genomic control based on chip markers. 
For the thyroid cancer GWAS the correction factor based on the genomic control is 1.14. For the 
GWAS on goiter, TSH, FT3 and FT4 the correction factor based on the genomic control is 1.08, 
1.33, 1.02, and 1.16, respectively. 
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